We are live on ! Find out more
SMV

Sofinnova Management VIII Portfolio holdings

AUM $183M
1-Year Est. Return 4.18%
This Fund
S&P 500
This Quarter Est. Return
-0.66%
1 Year Est. Return
+4.18%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$178M
AUM Growth
–
Cap. Flow
+$179M
Cap. Flow %
100.58%
Top 10 Hldgs %
100%
Holding
9
New
9
Increased
–
Reduced
–
Closed
–

Top Buys

Rank Stock Value
1
ACRS icon
Aclaris Therapeutics
ACRS
+$58.4M
2
ONCE
Spark Therapeutics, Inc. Common Stock
ONCE
+$48.5M
3
ARAV
Aravive, Inc. Common Stock
ARAV
+$29.8M
4
NTRA icon
Natera
NTRA
+$17.1M
5
INNL
Innocoll Holdings plc Ordinary Shares
INNL
+$7.81M

Top Sells

No sells this quarter

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ACRS icon
1
Aclaris Therapeutics
ACRS
$842M
$62.1M 34.97%
+2,289,480
New +$58.4M
ONCE
2
DELISTED
Spark Therapeutics, Inc. Common Stock
ONCE
$45.2M 25.41%
+904,986
New +$48.5M
ARAV
3
DELISTED
Aravive, Inc. Common Stock
ARAV
$35.2M 19.8%
+393,663
New +$29.8M
NTRA icon
4
Natera
NTRA
$44.8B
$18.2M 10.22%
+1,550,280
New +$17.1M
CYTO
5
DELISTED
Altamira Therapeutics Ltd
CYTO
$6.22M 3.5%
+73
New +$7.24M
SYBX
6
DELISTED
Synlogic
SYBX
$5.36M 3.01%
+28,332
New +$4.57M
OCGN icon
7
Ocugen
OCGN
$451M
$3.47M 1.95%
+34,617
New +$4.8M
INNL
8
DELISTED
Innocoll Holdings plc Ordinary Shares
INNL
$1.45M 0.82%
+2,103,173
New +$7.81M
SPHS
9
DELISTED
Sophiris Bio, Inc.
SPHS
$560K 0.32%
+200,000
New +$566K

Similar funds

BIC
Bridges Investment Counsel Omaha, Nebraska $181M AUM 21.67% 1-Year Est. Return
CCM
CrestPoint Capital Management Four Seasons, Missouri $180M AUM 21.37% 1-Year Est. Return
YP
Yellowstone Partners Idaho Falls, Idaho $177M AUM
EI
Elkhorn Investments Chicago, Illinois $191M AUM 17.81% 1-Year Est. Return
W
WealthShield Cary, North Carolina $164M AUM
IA
IPL Advisers New York $158M AUM 18.16% 1-Year Est. Return
WI
Welch Investments Birmingham, Alabama $157M AUM 17.66% 1-Year Est. Return
TCM
Texan Capital Management Houston, Texas $154M AUM 98.25% 1-Year Est. Return

Sofinnova Management VIII's Q4 2016 Portfolio in Review

Q4 2016 is the first quarter with a 13F filing on record for Sofinnova Management VIII, which disclosed 9 positions worth $178M. Its ten largest holdings account for 100% of the portfolio.

Its largest position is Aclaris Therapeutics: 2,289,480 shares worth $62.1M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets.

  • Sofinnova Management VIII's largest Q4 2016 buy was Aclaris Therapeutics: 2,289,480 shares worth $62.1M.
  • Sofinnova Management VIII's ten largest holdings make up 100% of its $178M portfolio in Q4 2016.
  • Sofinnova Management VIII disclosed 9 positions in Q4 2016, its first 13F filing on record.

Based on Sofinnova Management VIII's 13F filing for Q4 2016, filed 14 Feb 2017.